Why the study?
Does the CAMF regimen improve objective responses and survival compared to the CVMF regimen in postmenopausal females with metastatic breast cancer?
Does the CAMF regimen improve objective responses and survival compared to the CVMF regimen in postmenopausal females with metastatic breast cancer?
In postmenopausal women with metastatic breast cancer, an adriamycin-based regimen (CAMF) did not significantly differ from a vinblastine-based regimen (CVMF) in objective response or prognosis.
Neither regimen shows superiority in responses or prognosis; confirms equivalence of CAMF and CVMF in postmenopausal metastatic breast cancer.
Two regimens of chemotherapy for metastatic breast cancer were compared in a randomized controlled fashion. Regimen 1 consisted of cyclophosphamide, vinblastine, methotrexate and 5-fluorouracil (CVMF). Regimen 2 consisted of cyclophosphamide, adriamycin, methotrexate and 5-fluorouracil (CAMF). The patient population consisted of both black and white postmenopausal females who had not received any prior chemotherapy. Objective responses were observed in 25/57 patients treated with CVMF and in 28/51 patients treated with CAMF. Neither race nor choice of chemotherapeutic regimen affected prognosis, although there were differences in the pattern of metastatic involvement between the two racial groups. The median duration of survival of patients who responded to therapy has not yet been reached but will be in excess of 12 months.
No takes yet. Share an insight, caveat, or question.
Bezwoda et al. (1979) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: